ECSP20018586A - Compuestos que contienen pirazolopirimidinona y sus usos - Google Patents

Compuestos que contienen pirazolopirimidinona y sus usos

Info

Publication number
ECSP20018586A
ECSP20018586A ECSENADI202018586A ECDI202018586A ECSP20018586A EC SP20018586 A ECSP20018586 A EC SP20018586A EC SENADI202018586 A ECSENADI202018586 A EC SENADI202018586A EC DI202018586 A ECDI202018586 A EC DI202018586A EC SP20018586 A ECSP20018586 A EC SP20018586A
Authority
EC
Ecuador
Prior art keywords
compounds
compounds containing
relates
present
pyrazolopyrimidinone
Prior art date
Application number
ECSENADI202018586A
Other languages
English (en)
Inventor
Leonard Sung
Laura Gillard
Taras Rybak
Mariam Zaky
Hossein Ismaili
George Edwin Katibah
Stephane Ciblat
Tucker Curran Roberts
Vu Linh Ly
Franck Raeppel
Chudi Obioma Ndubaku
Yeeman K Ramtohul
Original Assignee
Aduro Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aduro Biotech Inc filed Critical Aduro Biotech Inc
Publication of ECSP20018586A publication Critical patent/ECSP20018586A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a compuestos de pirazolopirimidinona. La presente invención también se refiere a composiciones farmacéuticas que contienen estos compuestos y a métodos para tratar enfermedades autoinmunitarias, inflamatorias y neurodegenerativas mediante la administración de estos compuestos y composiciones farmacéuticas a sujetos que los necesitan. La presente invención también se refiere al uso de tales compuestos para investigación u otros fines no terapéuticos.
ECSENADI202018586A 2017-09-15 2020-03-13 Compuestos que contienen pirazolopirimidinona y sus usos ECSP20018586A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762559482P 2017-09-15 2017-09-15
US201862633248P 2018-02-21 2018-02-21
US201862687769P 2018-06-20 2018-06-20

Publications (1)

Publication Number Publication Date
ECSP20018586A true ECSP20018586A (es) 2020-06-30

Family

ID=65723108

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202018586A ECSP20018586A (es) 2017-09-15 2020-03-13 Compuestos que contienen pirazolopirimidinona y sus usos

Country Status (22)

Country Link
US (1) US10738056B2 (es)
EP (1) EP3681888A4 (es)
JP (1) JP2020533376A (es)
KR (1) KR20200032751A (es)
CN (1) CN111212839A (es)
AU (1) AU2018331456B2 (es)
BR (1) BR112020003676A2 (es)
CA (1) CA3075751A1 (es)
CL (1) CL2020000544A1 (es)
CO (1) CO2020002107A2 (es)
CR (1) CR20200114A (es)
DO (1) DOP2020000051A (es)
EC (1) ECSP20018586A (es)
IL (1) IL273236A (es)
JO (1) JOP20200055A1 (es)
MA (1) MA50256A (es)
MX (1) MX2020002869A (es)
PE (1) PE20210340A1 (es)
PH (1) PH12020500500A1 (es)
SG (1) SG11202002218VA (es)
TW (1) TW201920185A (es)
WO (1) WO2019055750A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3034705C (en) 2016-08-31 2021-08-03 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
WO2019092660A1 (en) 2017-11-10 2019-05-16 Takeda Pharmaceutical Company Limited Sting modulator compounds, and methods of making and using
WO2019123340A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CA3093888A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
MX2022002152A (es) * 2019-08-21 2022-05-18 Scripps Research Inst Agonistas biciclicos del estimulador de genes de interferon sting.
CN110724143B (zh) * 2019-10-09 2021-03-23 清华大学 一种靶向btk蛋白降解化合物的制备及其在治疗自身免疫系统疾病与肿瘤中的应用
CN110627725B (zh) * 2019-10-14 2022-10-18 遵义医科大学 一种4-取代5-二氟甲基-3-硝基-1h-吡唑类化合物及其制备方法与应用
KR20230154292A (ko) 2019-11-25 2023-11-07 암젠 인크 델타-5 불포화효소 억제제로서의 헤테로시클릭 화합물 및 사용 방법
CN113248491B (zh) * 2020-02-11 2022-02-25 中国科学院上海药物研究所 一类取代的吲哚脲衍生物、合成方法及其用途
WO2021233851A1 (en) * 2020-05-20 2021-11-25 F. Hoffmann-La Roche Ag New malonitrile derivatives
JP2023525908A (ja) * 2020-05-20 2023-06-19 エフ． ホフマン－ラ ロシュ アーゲー Ｃｇａｓ阻害トリアゾロピリミドン誘導体
CN115551837A (zh) * 2020-05-20 2022-12-30 豪夫迈·罗氏有限公司 新型丙二腈衍生物
MX2023005381A (es) 2020-11-09 2023-05-23 Takeda Pharmaceuticals Co Conjugados de anticuerpo y farmaco.
CN114644633A (zh) * 2020-12-18 2022-06-21 北京诺诚健华医药科技有限公司 杂环类jak抑制剂
WO2022137082A1 (en) * 2020-12-22 2022-06-30 Novartis Ag Pyrrolo[3,2-b]pyridine derivatives useful in treating conditions associated with cgas
WO2022221188A1 (en) * 2021-04-13 2022-10-20 University Of Washington Designed constitutively active cyclic gmp-amp synthase as a genetically encoded stimulant of interferons

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS625362A (ja) 1985-06-30 1987-01-12 菊地　真 ハイパ−サ−ミア用加温装置
JPH02131235A (ja) 1988-11-12 1990-05-21 Fuji Photo Film Co Ltd 新規なカプラーを含有するハロゲン化銀写真感光材料
US5420128A (en) 1990-10-09 1995-05-30 Otsuka Pharmaceutical Co., Ltd. Pyrimidine derivatives, method of manufacturing the same, and androgen inhibitor
DE69130683T2 (de) * 1991-04-22 1999-05-06 Otsuka Pharma Co Ltd PYRAZOLO[1,5-a]PYRIMIDINDERIVATE UND SIE ENTHALTENDE ANTIINFLAMMATORISCHE MITTEL
EP0795555A4 (en) 1995-09-28 1998-01-07 Otsuka Pharma Co Ltd ANALGETICS
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
FR2746309B1 (fr) 1996-03-22 1998-04-17 Oreal Composition de teinture des fibres keratiniques contenant des pyrazolopyrimidineoxo ; leur utilisation pour la teinture comme coupleurs, procedes de teinture
US6060478A (en) 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
ID23177A (id) 1997-03-14 2000-03-23 Otsuka Pharma Co Ltd Turunan pirimidin baru
JP3625362B2 (ja) 1997-09-08 2005-03-02 コニカミノルタホールディングス株式会社 感熱転写記録材料及び感熱転写記録方法
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US7405235B2 (en) 2001-05-04 2008-07-29 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
WO2004001058A2 (en) 2001-05-04 2003-12-31 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
US7449488B2 (en) 2002-06-04 2008-11-11 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
AU2003240488A1 (en) 2002-06-04 2003-12-19 Neogenesis Pharmaceuticals, Inc. Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
AU2003291226B2 (en) 2002-11-01 2009-06-04 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
JP2005008581A (ja) * 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
DE10356579A1 (de) 2003-12-04 2005-07-07 Merck Patent Gmbh Aminderivate
US20060160799A1 (en) 2004-04-23 2006-07-20 Alekshun Michael N Transcription factor modulating compounds and methods of use thereof
ES2396177T3 (es) 2007-08-14 2013-02-19 Bayer Intellectual Property Gmbh Pirimidinas bicíclicas fusionadas
WO2009039323A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009071705A1 (en) * 2007-12-07 2009-06-11 Galapagos Nv Pyrazolepyrimidine compounds useful for the treatment of degenerative & inflammatory diseases
WO2009076352A1 (en) * 2007-12-11 2009-06-18 Schering Corporation Gamma secretase modulators
CN101925603B (zh) 2007-12-13 2013-12-04 沃泰克斯药物股份有限公司 囊性纤维化跨膜通道调节因子的调节剂
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
CN101906105B (zh) 2009-06-08 2013-01-16 河北医科大学 吡唑并[1，5-a]嘧啶酮衍生物及其药物组合物以及其用途
CN101671336B (zh) 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
BR112013003097B1 (pt) * 2010-08-12 2021-03-16 Boehringer Ingelheim International Gmbh 6-cicloalquil-pirazolopirimidinonas e composição farmacêutica
BR112013008695A2 (pt) 2010-09-27 2016-06-21 Proximagen Ltd compostos de 7-hidróxi-pirazol[1,5-a] pirimidina e seu uso como antagonistas do receptor ccr2
US10953012B2 (en) * 2011-04-26 2021-03-23 Bioenergenix Llc Heterocyclic compounds for the inhibition of pask
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
US20130317021A1 (en) 2012-05-23 2013-11-28 Savira Pharmaceuticals Gmbh Heterocyclic pyrimidine carbonic acid derivatives which are useful in the treatment, amelioration or prevention of a viral disease
MX2014014106A (es) 2012-05-23 2015-09-25 Savira Pharmaceuticals Gmbh Derivados de acido 7-oxo-tiazolopiridinocarbonico y su uso en el tratamiento, disminucion o prevencion de una enfermedad viral.
CN104619699A (zh) 2012-08-06 2015-05-13 萨维拉制药有限公司 二羟基嘧啶碳酸衍生物以及它们在治疗、改善或预防病毒疾病中的用途
MX2015011898A (es) 2013-03-13 2016-05-05 Genentech Inc Compuestos de pirazolo y usos de los mismos.
KR20160049003A (ko) * 2013-09-05 2016-05-04 제넨테크, 인크. 항증식성 화합물
WO2015135094A1 (en) 2014-03-13 2015-09-17 Genentech, Inc. Therapeutic compounds and uses thereof
US10849901B2 (en) 2014-05-27 2020-12-01 Navigen, Inc. Arf6 inhibitors and methods of synthesis and use thereof
CN106146508A (zh) * 2015-03-19 2016-11-23 浙江导明医药科技有限公司 优化的联合用药及其治疗癌症和自身免疫疾病的用途
AU2016340527B2 (en) 2015-10-23 2020-09-17 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3394032A4 (en) 2015-12-21 2019-09-18 The University of Chicago COMPOUNDS AND METHODS OF TREATMENT, DETECTION AND IDENTIFICATION OF COMPOUNDS FOR THE TREATMENT OF PARASITIC ILLNESSES BY APICOMPLEXA
EP3442974B8 (en) 2016-04-15 2023-07-12 Elanco Animal Health GmbH Pyrazolopyrimidine derivatives
US20200317674A1 (en) 2016-06-03 2020-10-08 An2H Discovery Limited Pyrazolopyrimidine derivatives and the compositions and methods of treatment regarding the same
WO2018039972A1 (en) 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
CA3034705C (en) 2016-08-31 2021-08-03 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
WO2018229683A1 (en) 2017-06-15 2018-12-20 Novartis Ag 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
KR20200134203A (ko) * 2017-08-21 2020-12-01 나비젠, 인코포레이티드 Ａｒｆ6 억제제 및 관련 방법

Also Published As

Publication number Publication date
IL273236A (en) 2020-04-30
EP3681888A1 (en) 2020-07-22
US20190119285A1 (en) 2019-04-25
JP2020533376A (ja) 2020-11-19
MX2020002869A (es) 2020-07-24
WO2019055750A1 (en) 2019-03-21
CO2020002107A2 (es) 2020-05-29
CR20200114A (es) 2020-06-01
CL2020000544A1 (es) 2020-10-02
US10738056B2 (en) 2020-08-11
CN111212839A (zh) 2020-05-29
CA3075751A1 (en) 2019-03-21
PH12020500500A1 (en) 2021-03-01
TW201920185A (zh) 2019-06-01
EP3681888A4 (en) 2021-07-07
JOP20200055A1 (ar) 2020-03-10
AU2018331456B2 (en) 2020-10-08
AU2018331456A1 (en) 2020-03-05
KR20200032751A (ko) 2020-03-26
SG11202002218VA (en) 2020-04-29
PE20210340A1 (es) 2021-02-22
DOP2020000051A (es) 2020-08-15
MA50256A (fr) 2020-07-22
BR112020003676A2 (pt) 2020-09-01

Similar Documents

Publication Publication Date Title
ECSP20018586A (es) Compuestos que contienen pirazolopirimidinona y sus usos
SV2016005311A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
CL2016001579A1 (es) Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen, así como su uso para la preparación de medicamentos.
SV2018005771A (es) Derivados de piridiniltriazol sustituidos con amida y usos de estos
CR20180175A (es) Anticuerpos anti-cd19 humano con alta afinidad
DOP2017000298A (es) Reguladores de nrf2
CL2020000422A1 (es) Composiciones de glp-1 y sus usos.
EA201792047A1 (ru) Новые соединения
CL2018000622A1 (es) Acetamida tienodiazepinas de triazol y sus usos relacionados.
CL2017000372A1 (es) Composiciones novedosas, usos y métodos para hacerlas.
CL2017002106A1 (es) Anticuerpos contra tau y sus usos
EA201691259A1 (ru) РЕГУЛЯТОРЫ Nrf2
CO2018005315A2 (es) Moduladores de la interacción de sestrina-gator2 y sus usos
UY35427A (es) Compuestos y sus usos en la modulación de la hemoglobina
UY35425A (es) Compuestos y sus usos en la modulación de la hemoglobina
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
BR112018012262A2 (pt) composições de interleucina-15 e seus usos
UY35426A (es) Compuestos y sus usos en la modulación de la hemoglobina
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
CO2018002211A2 (es) Piridinona dicarboxamida para su uso como inhibidores de bromodominio
UY37221A (es) Derivados de feniltriazol sustituidos con amida y usos de estos
CO2019012767A2 (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo
GT201600027A (es) Inhibidores de rorc2 y sus métodos de uso
ECSP18018793A (es) Compuestos útiles para inhibir ror-gamma-t